Evolent Health, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter filing. Evolent provides specialty care management, total-cost-of-care management and administrative services to health plans and other payers. It acquired National Imaging Associates (NIA) on January 20, 2023, and combined its former two reporting segments into one segment during 2023.
Financial performance and position
| Metric | 2023 | 2022 | Change / context |
|---|---|---|---|
| Revenue | $1,963.9 million | $1,352.0 million | Up 45.3%; growth includes NIA and IPG, new partners and expansions. |
| Cost of revenue | $1,503.4 million | $1,035.4 million | 76.6% of revenue in both years. |
| Gross profit and margin | $460.5 million; 23.4% | $316.6 million; 23.4% | Calculated as revenue less cost of revenue. |
| Operating income (loss) | $(71.2) million | $3.6 million | 2023 operating margin was approximately (3.6)%, versus 0.3%. |
| Net loss attributable to common shareholders | $(142.3) million | $(19.2) million | 2023 included $29.2 million of preferred dividends and accretion. |
| Cash from operating activities | $142.6 million | $(11.6) million | Improved, with material effects from claims-reserve movements and working-capital timing. |
| Cash and cash equivalents | $192.8 million | $188.2 million | Restricted cash and investments were an additional $30.6 million. |
| Debt | $612.5 million principal; $597.0 million net carrying value | — | Year-end principal comprised $575.0 million of convertible notes and $37.5 million drawn on the revolver. |
Operating metrics and balance-sheet items
- Average lives on platform increased to 41.3 million unique members from 16.2 million, reflecting acquisitions and expanded services. Performance Suite average membership was 4.2 million versus 2.4 million; Specialty Technology and Services Suite was 69.5 million versus 14.9 million.
- Administrative Services revenue declined $111.3 million. Revenue growth in Performance Suite and Specialty Technology and Services Suite was partly offset by Medicaid enrollment declines following the end of the public health emergency.
- Accounts receivable, net, rose to $446.7 million from $254.7 million. Cook County Health represented 46.9% of short-term trade receivables and 15.7% of annual revenue.
- Current assets were $683.7 million and current liabilities $674.2 million at year-end. The company said it expected existing cash to cover working-capital and capital-expenditure needs for at least twelve months.
- Reserves for claims and performance-based arrangements increased to $404.0 million from $199.7 million. Goodwill was $1.12 billion and net intangible assets were $752.0 million.
Material changes and unusual items
- NIA contributed $242.1 million of revenue from its acquisition date through year-end. Total 2023 revenue also included $318.0 million from acquisitions and launches of new integrated products with NIA and IPG, according to management.
- Cost of revenue included higher claims costs from acquisitions and transitions of certain customers from administrative-services-only to risk-based contracts. Management cited $344.1 million of higher claims costs, partly offset by maturation of newer Performance Suite contracts.
- Operating expenses included a $24.1 million right-of-use asset impairment after decommissioning the Chicago lease, an $8.1 million loss on disposal of non-strategic assets and an $18.0 million loss from changes in contingent consideration fair value.
- The company recorded $21.0 million of loss on debt repayment/extinguishment, including prepayment premiums and accelerated amortization of financing costs. Interest expense increased to $54.2 million from $15.6 million.
- A $89.4 million income tax benefit reduced the reported loss from continuing operations; management attributed the benefit primarily to deferred tax liabilities established in acquisition accounting. The company also recorded a $62.0 million increase in its tax receivables agreement liability, which reached $107.9 million.
- Operating cash flow turned positive, but included a $204.3 million increase in claims and performance-based reserves. The filing also cites lower receipts from certain performance-based customers, including Cook County Health, and increased receivables.
Outlook, risks and contingencies
- The filing provides no numerical forward-year revenue or earnings guidance. Management expects cost of revenue to decline as a share of revenue over the longer term, depending on growth mix, and expects SG&A leverage as the business scales. It also expects depreciation and amortization to rise in future periods.
- The 2023 repositioning plan is intended to streamline operations and focus resources on specialty care. Charges were estimated at approximately $45.0 million over the plan’s life; $35.2 million had been recorded by year-end, with substantial completion anticipated in the first half of 2024.
- Key risks include integrating NIA, dependence on a small number of partners, contract termination or repricing, Medicaid redeterminations, healthcare regulation and audits, and estimating claims and medical costs under risk-bearing contracts. The claims reserve is a critical audit matter because it depends on actuarial assumptions, including completion factors and medical-cost trends.
- Debt and preferred-stock obligations are significant. The Series A Preferred Stock carries quarterly cash dividends at Adjusted Term SOFR plus 6.00%; $18.8 million of dividends were paid in 2023. Floating rates, debt covenants, conversion or redemption provisions, and potential dilution may affect liquidity and common shareholders.
- The company reported no material cybersecurity incidents in the three most recently completed fiscal years. Deloitte gave unqualified opinions on the financial statements and internal control over financial reporting; however, NIA, representing 31.0% of assets and 12.3% of revenue, was excluded from management’s 2023 internal-control assessment while integration continued.
- A shareholder demand concerning alleged oversight issues related to Passport Health Plan was under review. The board declined to bring the requested litigation in February 2024; the company said it could not estimate a possible loss range.
Important facts for investors to verify
- How much of revenue growth and future performance reflects organic expansion versus NIA/IPG acquisitions, and whether anticipated integration benefits are being realized.
- Whether the $404.0 million claims reserve is adequate as claims mature, and how reserve development affects margins and operating cash flow.
- Receivables collection and partner concentration, particularly Cook County Health’s 46.9% share of short-term trade receivables.
- Debt-service capacity, covenant headroom, floating-rate exposure, and the cash cost and terms of Series A Preferred Stock dividends and potential redemption or conversion.
- Progress and remaining costs under the repositioning plan, and whether the expected margin improvements materialize.
- The assumptions supporting acquisition-related intangible assets, goodwill, tax benefits and the $107.9 million TRA liability, including potential future cash payments.